Evidence map›Paper›PMID 39394121›Full record

ArticleBMC cancer2024

Construction and validation of a prognostic model of angiogenesis-related genes in multiple myeloma.

Rui Hu, Fengyu Chen, Xueting Yu, Zengzheng Li, Yujin Li, Shuai Feng, Jianqiong Liu, Huiyuan Li, Chengmin Shen, Xuezhong Gu and 1 more

Erratum issuedAbstract readValidation Study
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Rui Hu *Department of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Fengyu Chen *Department of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Xueting YuDepartment of Endocrinology, 920th Hospital of Joint Logistics Support Force,PLA, Kunming, China.
Zengzheng LiDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Yujin LiDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Shuai FengDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Jianqiong LiuDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Huiyuan LiDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Chengmin ShenDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China.
Xuezhong GuDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China. gxz76@126.com.
Zhixiang LuDepartment of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Kunming, China. lzx70822@163.com.

Funding

the 920th Hospital of PLA Joint Logistics Support Force Science and Technology Program Youth Project 2023YGY2the National Natural Science Foundation of China 82360041the Open Project of Yunnan Blood Clinical Medical Center 2022LCZXKF-XY11, 2021LCZXXF-XY04, 2021LCZXXF-XY05, 2020LCZXKF-XY02the Yunnan Applied Basic Research Projects-Joint Fund for Applied Basic Research of Kunming Medical University, the Yunnan Provincial Department of Science and Technology No. 2018FE001 (-113)the Yunnan Health Training Project of High-level Talents NO. D-2018018
6 · The paper itself

Abstract

backgroundAngiogenesis is associated with tumour growth, infiltration, and metastasis. This study aimed to detect the mechanisms of angiogenesis-related genes (ARGs) in multiple myeloma (MM) and to construct a new prognostic model.

methodsMM research foundation (MMRF)-CoMMpass cohort, GSE47552, GSE57317, and ARGs were sourced from public databases. Differentially expressed genes (DEGs) in the tumour and control cohorts in GSE47552 were determined through differential expression analysis and were enriched with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Weighted gene coexpression network analysis (WGCNA) was applied to derive modules linked to the ARG scores and obtain module genes in GSE47552. Differentially expressed ARGs (DE-ARGs) were selected for subsequent analyses by overlapping DEGs and module genes. Furthermore, prognostic genes were selected using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses. Depending on the prognostic genes, a risk model was constructed, and risk scores were determined. Moreover, MM samples from MMRF-CoMMpass were sorted into high- and low-risk teams on account of the median risk score. Additionally, correlations among clinical characteristics, gene set variation analysis (GSVA), gene set enrichment analysis (GSEA), immune analysis, immunotherapy predictions and the mRNA‒miRNA‒lncRNA network were carried out.

resultsA total of 898 DEGs, 211 module genes, 24 DE-ARGs and three prognostic genes (AKAP12, C11orf80 and EMP1) were selected for this study. Enrichment analysis revealed that the DEGs were related to 86 GO terms, such as 'cytoplasmic translation', and 41 KEGG pathways, such as 'small cell lung cancer'. A prognostic gene-based risk model was created in MMRF-CoMMpass and confirmed with the GSE57317 dataset. Moreover, a nomogram was established on the basis of independent prognostic factors that have proven to be good predictors. In addition, the immune cell infiltration results suggested that memory B cells were enriched in the high-risk group and that immature B cells were enriched in the low-risk group. Finally, the mRNA‒miRNA‒lncRNA network demonstrated that hsa-miR-508-5p was tightly associated with EMP1 and AKAP12. RT‒qPCR was used to validate the expression of the genes associated with prognosis.

conclusionA new prognostic model of MM associated with ARGs was created and validated, providing a new perspective for exploring the connection between ARGs and MM.

Indexed as

Gene Expression ProfilingMultiple MyelomaNeovascularization, PathologicAngiogenesisBiomarkers, TumorDatabases, GeneticGene Expression Regulation, NeoplasticGene OntologyGene Regulatory NetworksHumansPrognosisBiomarkers, TumorAngiogenesis-related genesGEOImmune microenvironmentMultiple myelomaPrognosis

Identifiers

PMID39394121
PMCPMC11470605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.